首页> 美国卫生研究院文献>Clinical Molecular Pathology >Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease.
【2h】

Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease.

机译:慢性肝病患者的可溶性ICAM-1浓度升高迟发型超敏性皮肤试验受损。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIMS/BACKGROUND: Soluble ICAM-1 may act as an antagonist of the membrane bound form, which is essential for the adhesion of leucocytes to endothelial cells. The aim of this study was to investigate whether the presence of high concentrations of soluble ICAM-1 are related to the impairment of delayed-type hypersensitivity reactions. METHODS: The study population comprised 73 patients (53 men and 20 women) with chronic liver disease (19 with chronic hepatitis, 36 with cirrhosis and 18 with hepatocellular carcinoma), and 21 age-matched controls (11 men and 10 women). Serum soluble ICAM-1 was measured using an enzyme immunoassay. Skin tests for seven different antigens (tetanus, diphtheria, streptococcus group C, tuberculin, Candida, tricophyton, and proteus) were considered positive when diameters > or = 2 mm were recorded; the diameters of positive tests were added to calculate a cumulative score. RESULTS: Patients with chronic liver disease had fewer positive skin tests (median 2) and a lower cumulative score (median 7) than controls (median 3 and 12, respectively). Multivariate analysis suggested the existence of an independent association between alkaline phosphatase and anergy to skin tests and between soluble ICAM-1 concentrations and the cumulative score. CONCLUSIONS: The strong association observed between increased soluble ICAM-1 concentrations and impairment of delayed-type hypersensitivity skin tests suggests that soluble ICAM-1 may be implicated in the immune depression seen in patients with chronic liver disease.
机译:目的/背景:可溶性ICAM-1可以作为膜结合形式的拮抗剂,这对于白细胞与内皮细胞的粘附至关重要。这项研究的目的是调查高浓度的可溶性ICAM-1的存在是否与迟发型超敏反应的损害有关。方法:研究人群包括73例慢性肝病患者(53例男性和20例女性)(19例慢性肝炎,36例肝硬化和18例肝细胞癌)以及21例年龄匹配的对照组(11例男性和10例女性)。使用酶免疫测定法测量血清可溶性ICAM-1。当记录到直径大于或等于2 mm时,对七个不同抗原(破伤风,白喉,C链球菌,结核菌素,念珠菌,三生藻和变形杆菌)的皮肤试验被认为是阳性;将阳性测试的直径相加以计算累积分数。结果:与对照组(分别为中位数3和12)相比,患有慢性肝病的患者的阳性皮肤测试(中位数2)更少,累积得分(中位数7)更低。多变量分析表明,碱性磷酸酶与皮肤试验无反应之间以及可溶性ICAM-1浓度和累积评分之间存在独立的关联。结论:可溶性ICAM-1浓度增加与延迟型超敏性皮肤试验受损之间密切相关,这表明可溶性ICAM-1可能与慢性肝病患者的免疫抑制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号